Silexion Therapeutics

Silexion Therapeutics

Biotechnology
Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.

$1.1M

Market Cap • 11/17/2026

2008

(18 years)

Founded

2024

(2 years ago)

IPO

NASDAQ

Listing Exchange

Flag of Israel

Israel

Country

Valuation

P/B

0,4

P/S

—

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

4,6

EPS

—

Market Cap

Market Cap

1,1M

EV

-3,3M

EV/Revenue

—

EV/EBITDA

0,2

EV/EBIT

0,2

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-393,8%

Total Yield

-393,8%

Payout

0%

Retained Earnings

-64M

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

440%

Capex/OCF

-0,4%

SBC/OCF

—

% PPE

4,9%

% Goodwill

0%

ROE

—

ROIC

—

Leverage

N.D./EBITDA

0,3

Debt/Equity

0%

Current Ratio

1,7

Quick Ratio

1,3

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium